MANSFIELD, MA, 3Daughters, a clinical development company, announces closing of the first tranche in excess of $2 million in a Seed Round.
3Daughters, a clinical development company fueling evolutionary healthcare for women, announces closing of the first tranche in excess of $2 million in a Seed Round. This round was led by Thairm Bio, with a group of life science investors, and joined by the Argosy Foundation, Wexford Science and Technology, LLC, UMass Amherst, and other undisclosed investors.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
